The US FDA conducted a product-specific pre-approval inspection at the company’s Pune biotech facility from Sept. 8 to Sept.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to develop and commercialize OCU400, Ocugen’s ...